NASDAQ:RGNX - Regenxbio Stock Price, Forecast & News

Regenxbio trades on the NASDAQ under the ticker symbol "RGNX."

Regenxbio Inc (NASDAQ:RGNX) released its earnings results on Wednesday, February, 26th. The biotechnology company reported ($0.72) EPS for the quarter, missing the Zacks' consensus estimate of ($0.44) by $0.28. The biotechnology company had revenue of $11.77 million for the quarter, compared to the consensus estimate of $39.67 million. Regenxbio had a negative return on equity of 25.21% and a negative net margin of 268.88%. View Regenxbio's Earnings History.

Regenxbio is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Regenxbio.

6 analysts have issued 12-month price objectives for Regenxbio's shares. Their forecasts range from $37.00 to $150.00. On average, they expect Regenxbio's stock price to reach $77.50 in the next year. This suggests a possible upside of 93.8% from the stock's current price. View Analyst Price Targets for Regenxbio.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regenxbio in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Regenxbio.

News articles about RGNX stock have trended very negative this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Regenxbio earned a news sentiment score of -4.0 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the company's share price in the next few days. View News Stories for Regenxbio.

Regenxbio saw a increase in short interest during the month of February. As of February 14th, there was short interest totalling 4,940,000 shares, an increase of 17.3% from the January 30th total of 4,210,000 shares. Based on an average trading volume of 472,500 shares, the days-to-cover ratio is currently 10.5 days. Approximately 14.8% of the company's stock are short sold. View Regenxbio's Current Options Chain.

Some companies that are related to Regenxbio include argenx (ARGX), Acceleron Pharma (XLRN), China Biologic Products (CBPO), Repligen (RGEN), Spark Therapeutics (ONCE), Iovance Biotherapeutics (IOVA), bluebird bio (BLUE), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), Allogene Therapeutics (ALLO), Crispr Therapeutics (CRSP), Halozyme Therapeutics (HALO), Momenta Pharmaceuticals (MNTA), Audentes Therapeutics (BOLD) and Fate Therapeutics (FATE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Regenxbio investors own include NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), Visa (V), Amarin (AMRN), Exelixis (EXEL), Square (SQ), Immunomedics (IMMU), Voyager Therapeutics (VYGR) and Alibaba Group (BABA).

Regenxbio's stock is owned by a number of of retail and institutional investors. Top institutional investors include State Street Corp (5.10%), UBS Group AG (1.78%), Credit Suisse AG (1.38%), Kam Lawrence (1.27%), Geode Capital Management LLC (1.25%) and Korea Investment CORP (1.24%). Company insiders that own Regenxbio stock include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Luke M Beshar, Olivier Danos, Patrick J Christmas, Stephen Yoo and Vittal Vasista. View Institutional Ownership Trends for Regenxbio.

RGNX stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Rafferty Asset Management LLC, Bank of New York Mellon Corp, Citigroup Inc., SG Americas Securities LLC, P.A.W. Capital Corp, AQR Capital Management LLC and Franklin Resources Inc.. Company insiders that have sold Regenxbio company stock in the last year include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Olivier Danos, Patrick J Christmas and Vittal Vasista. View Insider Buying and Selling for Regenxbio.

RGNX stock was bought by a variety of institutional investors in the last quarter, including Kam Lawrence, UBS Group AG, Goldman Sachs Group Inc., Barclays PLC, Parkman Healthcare Partners LLC, Panagora Asset Management Inc., Rhenman & Partners Asset Management AB and Cubist Systematic Strategies LLC. View Insider Buying and Selling for Regenxbio.

Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of RGNX stock can currently be purchased for approximately $40.00.

Regenxbio has a market capitalization of $1.49 billion and generates $35.23 million in revenue each year. The biotechnology company earns $99.94 million in net income (profit) each year or ($3.26) on an earnings per share basis. Regenxbio employs 192 workers across the globe.View Additional Information About Regenxbio.

The official website for Regenxbio is http://www.regenxbio.com/.

Regenxbio's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-552-8181 or via email at [email protected]